Market Cap 32.91M
Revenue (ttm) 0.00
Net Income (ttm) -38.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 6.18
Volume 54,900
Avg Vol 76,444
Day's Range N/A - N/A
Shares Out 6.45M
Stochastic %K 62%
Beta -1.88
Analysts Strong Sell
Price Target $13.50

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 996 5252
Fax: 781 642 0399
Address:
1167 Massachusetts Avenue, Arlington, United States
PennyStockChasers
PennyStockChasers Jul. 5 at 11:24 PM
$KALA Been a while since we got news
0 · Reply
TomMac64
TomMac64 Jul. 5 at 11:08 AM
$BIVI $KALA $SLS $TCRX We don’t care we have our hands full here !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!’nnn
0 · Reply
cea
cea Jul. 5 at 7:27 AM
$BIVI $KALA $SLS $TCRX @YasirTrades A quick view of $GLMD doesn’t support your position. Corporate presentation hasn’t been updated in 2 years: this is a concern. Looks like a pivot from NASH to GI oncology two years ago, pausing a Phase 3 study for lack of performance, but still in early clinical trails (Phase 1) with the pivot; no revenue streams. Unlikely to be an investable equity for at least 4 to 5 years. If I’m wrong, point me in the right direction for due diligence. Need to do better if you’re going to spam other boards; you’ll just end up getting blocked.
2 · Reply
InsaneTang
InsaneTang Jul. 3 at 11:39 AM
$SNGX $SNGX - MICRO FLOAT BIOTECH ON PARTNERSHIP WATCH 👀 Around 3.3M float. No RS. Pipeline has multiple irons in the fire: SGX301 (HyBryte), SGX302, SGX945… and now they’ve completed US manufacturing transfer. Phase 2/3 data incoming. But the BIG move? A potential partnership. Any co-dev or licensing deal = 🚀 due to tiny float. Think $KALA, $TTOO-style squeeze if terms are right. Shorts already light (under 1% float) $5+ not crazy if the right name signs on. Watch for PRs and volume spike. No one’s looking… yet.
0 · Reply
Neriono
Neriono Jun. 27 at 4:33 PM
0 · Reply
StockScanners
StockScanners Jun. 27 at 1:13 AM
$KALA We reached 5.39, ching ching, lets go team! follow for next banger
0 · Reply
Wallst45
Wallst45 Jun. 26 at 11:31 PM
$KALA some news incoming
0 · Reply
JL_TradeZ
JL_TradeZ Jun. 26 at 7:02 PM
$KALA is still under cash value with only 5.3M float and a confirmed Q3 catalyst. Oppenheimer gave a $15 PT and big funds are already positioned. Setup confirmed across all timeframes with volume rotation and stacked EMAs. If it reclaims 5.35, this can speed up fast toward 5.86 and 6.12+ Still early if volume kicks in. Watching closely
0 · Reply
EDayTrade
EDayTrade Jun. 26 at 5:20 PM
$KALA Back to $11 maybe??? News coming next week???
0 · Reply
StockScanners
StockScanners Jun. 25 at 11:56 PM
$KALA Keep watch if this holds above 4.60
0 · Reply
Latest News on KALA
KALA BIO to Present at Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 5 weeks ago

KALA BIO to Present at Jefferies Global Healthcare Conference


KALA BIO Announces Chief Executive Officer Transition

Feb 12, 2025, 8:00 AM EST - 5 months ago

KALA BIO Announces Chief Executive Officer Transition


KALA BIO Announces $10,750,000 Private Placement

Dec 30, 2024, 8:00 AM EST - 6 months ago

KALA BIO Announces $10,750,000 Private Placement


Kala Pharmaceuticals Announces Reverse Stock Split

Oct 20, 2022, 7:30 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Reverse Stock Split


Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 10:17 AM EDT - 3 years ago

Why Kala Pharmaceuticals Shares Are Rising Today


This Microcap Pharma Stock Almost Doubled Today - Read Why

Mar 8, 2022, 4:19 PM EST - 3 years ago

This Microcap Pharma Stock Almost Doubled Today - Read Why


Kala Pharma Acquires Ocular Surface Disease-Focused Company

Nov 15, 2021, 3:15 PM EST - 3 years ago

Kala Pharma Acquires Ocular Surface Disease-Focused Company


PennyStockChasers
PennyStockChasers Jul. 5 at 11:24 PM
$KALA Been a while since we got news
0 · Reply
TomMac64
TomMac64 Jul. 5 at 11:08 AM
$BIVI $KALA $SLS $TCRX We don’t care we have our hands full here !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!’nnn
0 · Reply
cea
cea Jul. 5 at 7:27 AM
$BIVI $KALA $SLS $TCRX @YasirTrades A quick view of $GLMD doesn’t support your position. Corporate presentation hasn’t been updated in 2 years: this is a concern. Looks like a pivot from NASH to GI oncology two years ago, pausing a Phase 3 study for lack of performance, but still in early clinical trails (Phase 1) with the pivot; no revenue streams. Unlikely to be an investable equity for at least 4 to 5 years. If I’m wrong, point me in the right direction for due diligence. Need to do better if you’re going to spam other boards; you’ll just end up getting blocked.
2 · Reply
InsaneTang
InsaneTang Jul. 3 at 11:39 AM
$SNGX $SNGX - MICRO FLOAT BIOTECH ON PARTNERSHIP WATCH 👀 Around 3.3M float. No RS. Pipeline has multiple irons in the fire: SGX301 (HyBryte), SGX302, SGX945… and now they’ve completed US manufacturing transfer. Phase 2/3 data incoming. But the BIG move? A potential partnership. Any co-dev or licensing deal = 🚀 due to tiny float. Think $KALA, $TTOO-style squeeze if terms are right. Shorts already light (under 1% float) $5+ not crazy if the right name signs on. Watch for PRs and volume spike. No one’s looking… yet.
0 · Reply
Neriono
Neriono Jun. 27 at 4:33 PM
0 · Reply
StockScanners
StockScanners Jun. 27 at 1:13 AM
$KALA We reached 5.39, ching ching, lets go team! follow for next banger
0 · Reply
Wallst45
Wallst45 Jun. 26 at 11:31 PM
$KALA some news incoming
0 · Reply
JL_TradeZ
JL_TradeZ Jun. 26 at 7:02 PM
$KALA is still under cash value with only 5.3M float and a confirmed Q3 catalyst. Oppenheimer gave a $15 PT and big funds are already positioned. Setup confirmed across all timeframes with volume rotation and stacked EMAs. If it reclaims 5.35, this can speed up fast toward 5.86 and 6.12+ Still early if volume kicks in. Watching closely
0 · Reply
EDayTrade
EDayTrade Jun. 26 at 5:20 PM
$KALA Back to $11 maybe??? News coming next week???
0 · Reply
StockScanners
StockScanners Jun. 25 at 11:56 PM
$KALA Keep watch if this holds above 4.60
0 · Reply
PharmaExpert
PharmaExpert Jun. 25 at 7:40 PM
$AKBA, $GCTK, $PSTV, $VYNE, $KALA 🔥🔥🔥🔥🔥
3 · Reply
Chartist0_0
Chartist0_0 Jun. 25 at 4:21 PM
$KALA added 500s before the run. 10$ incoming
0 · Reply
jParkz
jParkz Jun. 25 at 3:30 PM
$KALA Nhttps://marketwirenews.com/news-releases/kala-pharmaceuticals-inc-nasdaq-kala-rises-sharply-i-4857487471697108.html ews Article Kala Pharmaceuticals Inc. (NASDAQ: KALA) Rises Sharply in 6/25 Early Trading Session
0 · Reply
Wallst45
Wallst45 Jun. 25 at 3:28 PM
$KALA breakout above 5
0 · Reply
Idvst8
Idvst8 Jun. 25 at 2:46 PM
$KALA close to breaking out.
0 · Reply
GDog877
GDog877 Jun. 17 at 11:57 AM
$KALA Did you know the capital loss deduction limit has been stuck at $3,000 since 1978???? That’s nearly 50 years with zero adjustment for inflation. Imagine still being limited to a $3K deduction 30 years from now—while everything else keeps getting more expensive. That’s why I support the Capital Loss Inflation Fairness Act (H.R. 2684), which would raise the limit and adjust it for inflation going forward. Most retail investors will take losses at some point. This bill is a common-sense update that reflects today’s economic reality. 👉 You can learn more about the bill here: https://norman.house.gov/news/documentsingle.aspx?DocumentID=1611 📞 Find your representative and ask them to support it: www.house.gov/representatives/find-your-representative
0 · Reply
Wallst45
Wallst45 Jun. 12 at 3:59 PM
$KALA squeeze it now
0 · Reply
matmasr
matmasr Jun. 10 at 9:21 PM
$KALA Heating up. With such a low float, this can run.
0 · Reply
Stockswingalert
Stockswingalert Jun. 10 at 8:28 PM
$KALA 20.44% thank you for coming to the Ted talk https://x.com/stockswingalert/status/1932530248891109512?s=46 Moms birthday dinner we getting steak and lobster now to celebrate 🍴🍴🍽️ Love and god bless you all 🙏🙏🙏
0 · Reply
PharmaExpert
PharmaExpert Jun. 10 at 6:59 PM
$AKBA, $ALT, $KALA, $LGVN, $CRDF 🔥🔥🔥🔥🔥
1 · Reply
Wallst45
Wallst45 Jun. 10 at 6:48 PM
$KALA squeeze
0 · Reply
FetchDog
FetchDog Jun. 10 at 6:28 PM
$KALA They need cash soon and will do an offering after P2b data which should come around august or september. That means that the powers that be (institutional investors Baker Bros, Perceptive, etc) need to pump this stock before the P2b data: to raise sufficient capital they need to do an offering at a much higher price. So this is going up until data is announced. Pumping this stock up is real easy to do with such light volume. Rebought this on august 4 at $3.93 after I saw a volume and price spike on august 3. I expect ~ $10 before data. If data is good, this can go quite a bit higher than $8, but the peak price is limited by moderate market size and fears of an offering. I'll hold until data, maybe sell ~ 20% before data.
1 · Reply